Taxotere Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With NRG1 Gene Fusion Advanced Solid Tumors
Conditions:   Non-Small Cell Lung Cancer;   Pancreatic Cancer;   Locally Advanced Solid Tumor;   Metastatic Solid Tumor Interventions:   Drug: HMBD-001;   Drug: Docetaxel;   Drug: Nab-paclitaxel;   Drug: Gemcitabine Sponsor:   Hummingbird Bioscience Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions:   Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib;   Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor:   Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With NRG1 Gene Fusion Advanced Solid Tumors
Conditions:   Non-Small Cell Lung Cancer;   Pancreatic Cancer;   Locally Advanced Solid Tumor;   Metastatic Solid Tumor Interventions:   Drug: HMBD-001;   Drug: Docetaxel;   Drug: Nab-paclitaxel;   Drug: Gemcitabine Sponsor:   Hummingbird Bioscience Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions:   Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib;   Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor:   Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With NRG1 Gene Fusion Advanced Solid Tumors
Conditions:   Non-Small Cell Lung Cancer;   Pancreatic Cancer;   Locally Advanced Solid Tumor;   Metastatic Solid Tumor Interventions:   Drug: HMBD-001;   Drug: Docetaxel;   Drug: Nab-paclitaxel;   Drug: Gemcitabine Sponsor:   Hummingbird Bioscience Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions:   Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib;   Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor:   Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With NRG1 Gene Fusion Advanced Solid Tumors
Conditions:   Non-Small Cell Lung Cancer;   Pancreatic Cancer;   Locally Advanced Solid Tumor;   Metastatic Solid Tumor Interventions:   Drug: HMBD-001;   Drug: Docetaxel;   Drug: Nab-paclitaxel;   Drug: Gemcitabine Sponsor:   Hummingbird Bioscience Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions:   Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib;   Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor:   Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With NRG1 Gene Fusion Advanced Solid Tumors
Conditions:   Non-Small Cell Lung Cancer;   Pancreatic Cancer;   Locally Advanced Solid Tumor;   Metastatic Solid Tumor Interventions:   Drug: HMBD-001;   Drug: Docetaxel;   Drug: Nab-paclitaxel;   Drug: Gemcitabine Sponsor:   Hummingbird Bioscience Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions:   Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib;   Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor:   Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With NRG1 Gene Fusion Advanced Solid Tumors
Conditions:   Non-Small Cell Lung Cancer;   Pancreatic Cancer;   Locally Advanced Solid Tumor;   Metastatic Solid Tumor Interventions:   Drug: HMBD-001;   Drug: Docetaxel;   Drug: Nab-paclitaxel;   Drug: Gemcitabine Sponsor:   Hummingbird Bioscience Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions:   Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib;   Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor:   Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With NRG1 Gene Fusion Advanced Solid Tumors
Conditions:   Non-Small Cell Lung Cancer;   Pancreatic Cancer;   Locally Advanced Solid Tumor;   Metastatic Solid Tumor Interventions:   Drug: HMBD-001;   Drug: Docetaxel;   Drug: Nab-paclitaxel;   Drug: Gemcitabine Sponsor:   Hummingbird Bioscience Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions:   Breast Cancer;   HER2-positive Breast Cancer Interventions:   Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib;   Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor:   Henan Cancer Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With NRG1 Gene Fusion Advanced Solid Tumors
Conditions:   Non-Small Cell Lung Cancer;   Pancreatic Cancer;   Locally Advanced Solid Tumor;   Metastatic Solid Tumor Interventions:   Drug: HMBD-001;   Drug: Docetaxel;   Drug: Nab-paclitaxel;   Drug: Gemcitabine Sponsor:   Hummingbird Bioscience Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 26, 2023 Category: Research Source Type: clinical trials